Mission
Quercis is studying the use of its novel, proprietary and orally available anti-thrombotic, anti-cancer, antiviral and immuno-modulatory platforms to deliver innovative, effective, safe and broadly accessible treatments to patients with potentially life-threatening conditions addressing significant unmet medical needs.
With its portfolio of PDI inhibitors and Mast Cell Activation Modulators– – Quercis Pharma is committed to develop next-generation anti-thrombotics that turn off the blood clotting mechanism instead of thinning the blood without increasing the risk of bruising and bleeding while addressing VTE in cancer and eventually their use to prevent thrombosis in high-risk Sickle-Cell Disease, Cardiac and Stroke patients.
Strong initial data has indicated potential anti-neoplastic effects of our PDI inhibitors. We are committed to understanding the contribution of PDI to cancer tumorigenesis and cancer metastasis.
The relationship between viral illness and thrombosis and how PDI influences this as well as inflammasome behavior in the presence of our drug candidates gives us real hope for future thrombosis prevention and treatment in cancer, viral illnesses and other diseases.
Quercis has a preliminary program in ALS where a combination of Zafirlukast and Kinisoquin™ is being tested.
Shortcomings of current treatment options in our lead indication of the prevention of venous thromboembolism (VTE) in cancer patients
Cancer patients can have 4-7×increased risk of developing VTE compared to general population (1).
Risk can be ~30% for glioblastoma patients within weeks of starting chemotherapy (2).
21%
VTE incidence post chemotherapy initiation, 12 months post-diagnosis in Pancreatic Cancer (3)
15%
VTE incidence post chemotherapy initiation, 12 months post-diagnosis in Lung Cancer (3)
12%
VTE incidence post chemotherapy initiation, 12 months post-diagnosis in Colorectal Cancer (3)
Cancer patients with VTE had 2.2× increase in mortality (versus matched cancer patients without VTE) (4). VTE is the 2nd leading cause of mortality in numerous cancer types (apart from cancer itself) (5), accounting for 9% of cancer-related deaths (6).
Traditional anticoagulants have potentially life-threatening side effects such as severe bleeding. Despite the high VTE occurrence and mortality impact, currently no standard of care is available.
Quercis Pharma is ready to execute its late-stage development program of Kinisoquin™ under an FDA approved SPA, if successful leading to the first drug approved to prevent thrombosis in all solid cancer types by end of 2026.
Quercis Pharma is preparing to run a phase II proof of concept studies in Ovarian cancer and ALS.
Quercis Pharma is building up an experienced team to run these programs effectively.
Kinisoquin™
Based on our novel and proprietary anti-thrombotic, anti-cancer and antiviral platform to deliver innovative, effective, safe and broadly accessible treatments to patients with potentially life-threatening conditions addressing significant unmet medical needs.
With its portfolio of proprietary PDI inhibitors – that turn off the clotting process within the vascular system, instead of thinning the blood – Quercis Pharma is committed to develop next-generation anti-thrombotics that turn off the blood clotting mechanism without increasing the risk of bruising and bleeding addressing VTE (venous thromboembolism) in cancer and other patients at high risk of thrombosis.
Strong initial data has indicated potential anti-neoplastic effects of our PDI inhibitors. We are committed to understanding the contribution of PDI to cancer tumorigenesis and cancer metastasis.
The relationship between viral illness and thrombosis and how PDI influences this as well as inflammasome behavior in the presence of our drug candidates gives real hope for future thrombosis prevention and treatment in cancers, viral illness and other diseases.
Partnerships and Collaborations
